Advertisement
Canada markets close in 2 hours 58 minutes

  • S&P/TSX

    21,786.00
    -225.62 (-1.03%)
     

  • S&P 500

    5,068.49
    -47.68 (-0.93%)
     

  • DOW

    37,987.87
    -398.22 (-1.04%)
     

  • CAD/USD

    0.7270
    -0.0052 (-0.71%)
     

  • CRUDE OIL

    81.52
    -1.11 (-1.34%)
     

  • Bitcoin CAD

    86,000.88
    -925.06 (-1.06%)
     

  • CMC Crypto 200

    1,290.66
    -48.41 (-3.62%)
     

  • GOLD FUTURES

    2,307.50
    -50.20 (-2.13%)
     

  • RUSSELL 2000

    1,984.33
    -31.70 (-1.57%)
     

  • 10-Yr Bond

    4.6670
    +0.0530 (+1.15%)
     

  • NASDAQ

    15,808.50
    -174.58 (-1.09%)
     

  • VOLATILITY

    15.60
    +0.93 (+6.34%)
     

  • FTSE

    8,144.13
    -2.90 (-0.04%)
     

  • NIKKEI 225

    38,405.66
    +470.90 (+1.24%)
     

  • CAD/EUR

    0.6806
    -0.0018 (-0.26%)
     
MARKETS LIVE BLOG:

STOCKS SINK WITH FED IN FOCUS, AMAZON EARNINGS ON DECK

U.S. consumer confidence hits lowest level since July 2022

Creo Medical ends "pivotal" 2023 year with clear path to cashflow breakeven

News Direct
·1 min read

London, UK --News Direct-- Creo Medical Group PLC

Creo Medical Group CEO Craig Gulliford tells Proactive's Stephen Gunnion that 2023 was a pivotal year for the company.

Amid challenging market conditions, Creo successfully secured crucial funding, setting a foundation for enhanced operational focus rather than fundraising efforts. Key milestones included the launch of the Speedboat UltraSlim, a significant advancement in minimising medical device size, which led to the company's largest quarter in orders and technology uptake. This innovation, alongside the early market release of selected products, received positive feedback and significant regulatory clearances in the US and Europe, propelling Creo towards a robust setup for 2024.

ADVERTISEMENT

Furthermore, Creo announced progress with its SpydrBlade and MicroBlate programs, showcasing advancements in surgical technology and partnerships with leading robotic surgery firms.

Financially, Creo reported a 13% revenue increase to £30.8 million and a 10% reduction in operating costs, reflecting strategic shifts towards more cost-effective and revenue-generating operations.

These developments signal Creo's transition into a fully commercial business, with a clear path to cash flow breakeven by 2025.

Contact Details

Proactive UK Ltd

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/creo-medical-ends-pivotal-2023-year-with-clear-path-to-cashflow-breakeven-207604908